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Remarkable advances in understanding the pathogenesisof hereditary hemochromatosis have been made since1996, the year in which the HFE gene, which is respon-
sible for the vast majority of cases, was discovered.1 The
recognition of the central role of the iron regulatory hormone
hepcidin in the pathogenesis of hereditary hemochromatosis
has been particularly significant. In addition to HFE, defects in
four additional genes have been found to cause hereditary
hemochromatosis: hepcidin, transferrin receptor 2 (TFR2), hemo-
juvelin (HJV), and ferroportin.2 Interestingly, these genes each
encode for a protein that affects pathways influencing liver
hepcidin synthesis or its interaction with the cellular iron
export protein ferroportin. It is now clear that inadequate pro-
duction of hepcidin or response to it is responsible for the
excess dietary iron absorption and excess iron release from
macrophages stores, and consequent hyperferremia, which
characterize the classical hereditary hemochromatosis pheno-
type. For clinicians, the challenge is to diagnose hereditary
hemochromatosis before this hyperferremia leads to irre-
versible tissue damage. At the same time the clinician must
have ways to distinguish progressive heritable forms of iron
overload from increasingly common acquired diseases with
only moderately increased iron body stores, such as the meta-
bolic syndrome. This challenge has raised interest in the pos-
sibility that recent bench top discoveries might lead to novel
bedside laboratory tests. Two publications in this issue of
Haematologica are relevant to this possibility.3,4 In one study,
serum hepcidin levels were used to characterize the response
of patients with HFE- or TFR2-associated hereditary
hemochromatosis to an oral iron challenge.3 The other study
identifed several clinically significant orphan mutations in the
HFE gene.4 The contribution of each of these studies to a bet-
ter understanding of the pathogenesis of hereditary hemo -
chromatosis and the possible ways they might influence the
future diagnostic work-up and monitoring of iron overload
disorders are discussed.
The relation between iron status and hepcidin levels in
patients with HFE or TFR2 mutations
While there are many aspects of the regulation of hepcidin
expression by iron status that remain to be dissected, several
lines of evidence indicate that liver iron stores and circulating
ferri-transferrin (Tf-Fe2) each provide a signal to influence
hepatocyte hepcidin expression (Figure 1).5 An increase in liver
iron stores signals to hepcidin via certain members of the bone
morphogenetic protein (BMP) family, particularly BMP6, in an
autocrine and/or paracrine fashion. These extracellular signal-
ing molecules act on hepatocellular BMP receptors to activate
the intracellular SMAD signaling pathway and increase hep-
cidin transcription. Hemojuvelin is a BMP-coreceptor which
augments the BMP signal.6 Circulating transferrin appears to
be sensed via a hepatocellular complex which includes TFR1,
TFR2 and HFE.5 Defects in HFE and TFR2 lead to relatively
attenuated hepatocellular signaling to hepcidin via the MAPK
and/or BMP/SMAD pathways resulting in decreased circulat-
ing hepcidin levels.5,7-9 In this issue of Haematologica, Girelli et
al.3 describe their observation of a blunted serum hepcidin
response upon an oral iron challenge in overloaded HFE
C282Y homozygotes, confirming their previous findings using
urine hepcidin as a read out.10 This observation is consistent
Figure 1. Putative iron regulatory path-
ways of hepatocyte hepcidin synthesis.
This proposed model depicts two iron
signals to hepcidin, one mediated by
intracellular iron stores (Fe) and the
other by ferri-transferrin (Tf-Fe2). Hepato -
cellular iron stores increase the expres-
sion of bone morphogenetic protein 6
(BMP6), which serves as an autocrine
factor by interacting with surface BMP
receptors. Hemojuvelin (HJV) is a BMP
co-receptor which augments BMP bind-
ing. The consequent activation of intra-
cellular SMAD proteins transduces a sig-
nal to increase hepcidin transcription.
Under low iron conditions matriptase-2
(scissors) cleaves HJV from the cell sur-
face, weakening the BMP6 signal.
Extracellular Tf-Fe2 mediates a second
iron signal. In this schema Tf-Fe2 dis-
places HFE from TfR1. HFE is then freed
to interact with transferrin receptor 2
(TfR2). The HFE-TfR2 complex activates
hepcidin transcription via MAPK and/or
BMP/SMAD signaling. These pathways
have recently been reviewed.5
with the concept that iron signaling to hepcidin is attenu-
ated in the absence of HFE or TFR2. The inability to
manipulate transferrin saturation in the TFR2-mutated
patients, and the lack of specific measurement of differic
transferrin levels do, however, make it difficult to use these
studies to further substantiate the case that HFE and TFR2
act by sensing circulating differric transferrin.  
The iron-depleted HFE C282Y patients had very low
hepcidin levels, reflecting the combined effects of the HFE
mutation and phlebotomy on hepcidin expression. These
patients demonstrated an exaggerated increase in serum
iron levels upon iron loading, corroborating previous
reports directly measuring iron absorption.11 These obser-
vations draw further attention to the concern that lowering
hepcidin levels by phlebotomy in patients with hereditary
hemochromatosis may exacerbate the excess release of
iron into the circulation with an ensuing vicious circle with
such patients requiring more frequent maintenance phle-
botomies.8,10 Interestingly, oral iron loading did not cause
an exaggerated increase in serum iron levels in the phle-
botomized TFR2 patients and the untreated HFE patients,
despite their decreased hepcidin levels. These observations
suggest that dietary iron absorption was not increased in
these patients, and raises the possibility that compensatory
mechanisms exist to partially offset the hepcidin-mediated
effects on dietary iron absorption in hereditary hemochro-
matosis patients with elevated transferrin saturation.
Alternatively, the excess iron absorbed from the diet in
these hereditary hemochromatosis patients may have
entered the circulation as non-transferrin bound iron which
was rapidly cleared by the liver, and thus not reflected as a
change in systemic serum iron levels. 
Novel HFE mutations associated with hereditary
hemochromatosis
By far the most common genetic cause of hereditary
hemochromatosis is the C282Y mutation in HFE.1 The
consequent loss of a critical disulfide bond results in a loss
of HFE interaction with b2-microglobulin and decreased
trafficking of the HFE protein to the cell surface.12 A more
common, though less consequential HFE mutation leads
to a substitution of histidine for aspartate at nucleotide 63
(63H→D).1 The clinical implications of this mutation have
been an area of controversy. Several other allelic variants
have been reported, some of which of unknown signifi-
cance.13 In this issue of the journal, Aguilar-Martinez et al.
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Figure 2. Proposed diagnostic and
therapeutic algorithm for patients
with suspected hemochromatosis.
Orange boxes indicate the parts of the
guideline for  which the novel observa-
tions of the two publications in this
issue might provide opportunities for
improvement. * in case of heterozy-
gosity for the C282Y mutations start
searching for rare mutations in HFE in
the other allele. Serum hepcidin/fer-
ritin ratio may contribute to prioritiza-
tion of order of gene investigations. If
mutations are present the work-up is
similar to that for HFE hemochro-
matosis with respect to phlebotomy,
screening relatives, and periodic
screening of the liver in the case of
liver cirrhosis. ^ Low ferritin targets
may lead to excessive iron absorption.
Measurement of hepcidin could have
a role in monitoring phlebotomy and
to assess the ferritin target and fre-
quency of phlebotomy. Figure adapted
from van Bokhoven et al.15
describe three novel HFE mutations which, as compound
heterozygotes with the C282Y mutation, can lead to
hemochromatosis.4 Knowledge of mutations that func-
tionally affect HFE is important in currently recommended
strategies for the diagnostic work-up of the patient sus-
pected of having hereditary hemochromatosis.14-16
Diagnostic and monitoring strategies in hereditary
hemochromatosis
Unfortunately the early clinical signs and symptoms of
iron overload are both common and non-specific. At the
same time, the clinical penetrance of HFE mutations is
quite low, making population screening unjustified. A high
index of clinical suspicion is, therefore, essential for early
diagnosis. In recently developed evidence-based guide-
lines physicians are recommended to consider testing for
the disease in patients who have had unexplained symp-
toms consistent with iron toxicity for several months. The
combined measurement of serum iron concentration,
transferrin or total iron binding capacity (and calculation
of transferrin saturation) and ferritin concentration pro-
vide a simple and reliable first assessment of body iron
levels. HFE-gene testing is needed only in those cases with
increased transferrin saturation and ferritin and when
acquired causes of hyperferritinemia have been excluded
(Figure 2).14-16 If the patient is homozygous for HFE C282Y,
the diagnosis of HFE hemochromatosis can be established.
If serum iron parameters are elevated but the pathogno-
monic HFE genotype (C282Y homozygous) is absent,
determination of hepatic iron concentration is warranted.
Magnetic resonance imaging is increasingly recognized as
a useful non-invasive approach for this measurement,17
provided that proper software and calibration techniques
are used, which is often problematic. In the selected cases
with documented hepatic iron overload, a search for the
non-classical genetic defects is then indicated (Figure 2). In
their paper Aguilar-Martinez et al.4 suggest first testing for
rare HFE mutations in HFE C282Y heterozygous patients.
In the case that C282Y mutations are absent, the priority
order of the genes to be investigated might be directed by
clinical, laboratory and pathological features and the local
prevalence of certain gene defects. For instance in the case
of presentation at young age, certain genes (HJV and hep-
cidin) might be checked first, and in the south-west of the
Netherlands the N144H mutation in the ferroportin gene
might be the primary defect to look for.18 Ongoing
improvements in genomic techniques and their automa-
tion and interpretation will further assist in efficient gene
diagnosis19 and might preclude the need for prioritization,
undoubtedly affecting future guidelines. 
The measurement of serum hepcidin may also con-
tribute to the diagnostic and therapeutic monitoring algo-
rithms in patients with hereditary hemochromatosis. It is
still too early to determine at this stage the role of hepcidin
measurements in clinical practice; however, several com-
ments on this issue can be made. First, measurement of
hepcidin early in the diagnostic scheme cannot be current-
ly recommended, as testing for the HFE C282Y mutation
is straightforward and the majority of cases will be found
to have this mutation. Second, for patients who do not
have C282Y homozygosity but do have documented iron
overload, the hepcidin to ferritin ratio may be helpful in
the prioritization of the genes to be investigated, i.e. a low
ratio points towards defects in HJV and hepcidin genes
(Figure 2). Third, hepcidin could have a role in monitoring
phlebotomy and assessing the ferritin target and frequen-
cy of phlebotomy (Figure 2). Fourth, the differences in
hepcidin results obtained by enzyme-linked immunosor-
bent assays and mass-spectrometry methods, observed by
Girelli et al. in their study, show that before hepcidin
measurements can be used clinically, they need to be bet-
ter standardized.3,20 Results and recommendations from a
recent comparison of hepcidin levels from identical sam-
ples performed in different laboratories (the so-called hep-
cidin Round Robin 2) are expected in the course of 2011.
We expect that this effort will ultimately aid in the defini-
tion of clinical decision limits that can be broadly applied,
regardless of the technique or laboratory. Finally, as with
most other hormones, hepcidin values in patients suspect-
ed of having hereditary hemochromatosis should only be
interpreted as (in)appropriate in the context of other
indices of iron metabolism. 
Concluding remarks
The two articles in this issue of Haematologica provide
further evidence that rare HFE mutations may account for
body iron overload in C282Y heterozygous patients and
that iron depletion by phlebotomy lowers hepcidin levels
and increases iron absorption. These observations may be
considerations in future evidence-based clinical guidelines
for patients suspected of having hereditary hemochromato-
sis and inspire further studies on the role of serum hepcidin
measurements in the clinical care of these patients.
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The modern management of sickle cell disease (SCD)is based on three therapeutic approaches: bloodtransfusion (first used successfully in 1818), penicillin
(discovered in 1928) and hydroxycarbamide (first synthe-
sized in 1869).1 Dresler and Stein made this simple mole-
cule from hydroxylamine, hydrochloric acid and potassium
cyanide as a technical exercise in organic chemistry, as part
of a series of experiments generating derivatives of urea.
Hydroxycarbamide lay dormant for more than fifty years
until it was studied as part of an investigation into the tox-
icity of protein metabolites and found to produce a mega-
loblastic anemia, which was thought to mimic pernicious
anemia.2 In the early 1960s further in vitro studies showed
that hydroxycarbamide had activity against leukemia cell
lines and some tumors3 and this led to clinical studies
showing particular activity in myleoproliferative disorders.4
Increased fetal hemoglobin (HbF) production has long
been recognized as one of the key factors which can ame-
liorate SCD5 and in the 1970s 5-azacytidine was investigat-
ed as an HbF promoting agent because of its potential abil-
ity to reactivate silenced γ-globin genes by inhibiting the
methylation of deoxycytidine. Although 5-azacytidine suc-
cessfully increased HbF levels in baboons, and subsequent-
ly in patients with SCD and thalassemia, it was relatively
toxic.6 Hydroxycarbamide was also used in the early
baboon experiments, partly as a cytotoxic control because
it was known to have no effect on methylation and, per-
haps surprisingly, was also found to promote HbF synthe-
sis. Because of concerns about the toxicity of 5-azacytidine,
hydroxycarbamide was developed as a safer alternative
and an initial study in 2 adults with sickle cell anemia
(HbSS) (SCA) showed significant increases in both HbF and
total hemoglobin.7 Further observational studies followed,
before the Multicenter Study of Hydroxyurea (MSH) study
was published in 1995. In this double-blind randomized
controlled study, 152 adult patients with SCA were
assigned to hydroxycarbamide and 147 given placebo; the
hydroxycarbamide group showed reductions in the rate of
acute pain (median 2.5 vs. 4.5 episodes per year, P<0.001),
acute chest syndrome (25 vs. 51, P<0.001) and blood trans-
fusion (48 vs. 73, P<0.001).8 The study was stopped early
because of the reduction in acute pain in the hydroxycar-
bamide arm. The only other published randomized con-
trolled study involved a single-blind crossover study of 25
children and young adults with SCA treated for six months
with hydroxycarbamide and for six months with placebo;
hydroxycarbamide showed a treatment effect on reducing
the number of hospitalizations (P=0.0016) and total days in
hospital (P=0.0027).9 Since then a steady stream of registry,
observational and follow-up studies have followed, all
showing similar beneficial effects with increases in HbF
levels and reductions in some acute complications. Most
notably, two observational studies have suggested
increased survival associated with long-term hydroxycar-
bamide use. A follow-up study of the patients in the origi-
nal MSH study showed a 40% reduction in mortality in
those who chose to continue hydroxycarbamide after nine
years (P=0.04);10 a non-randomized study of patients in
Greece with SCA, HbS/b0thalassemia and HbS/b+tha-
lassemia showed the probability of 10-year survival was
86% for those taking hydroxycarbamide and 68% for
those not taking it (P=0.001).11
